Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease

NCT02327221 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Ovasave
DRUG: Placebo

Sponsor

TxCell